Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kelly, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kelly, W.
American Journal of Health-System Pharmacy, Vol 58, Issue 14, 1325-1329
Copyright © 2001 by American Society of Health-System Pharmacists

Articles

Potential risks and prevention, Part 2: Drug-induced permanent disabilities

WN Kelly


Potential risk factors for and the preventability of drug-induced permanent disabilities were studied. Case reports of adverse drug events (ADEs) published in Clin-Alert during 1978-97 were the source of information on drug-induced permanent disabilities. Patient, drug, and event variables were identified, and the causality, predictability, and preventability of each case were assessed. Data were entered into a relational database for analysis. The data indicated 227 cases of drug-induced permanent disabilities. Twenty-three percent of the cases were assessed as definite, 47% as probable, and 30% as possible. Twenty-nine percent of the patients were less than 10 years old, and 36% were considered healthy. The drug categories most commonly associated with a drug-induced permanent disability were antimicrobials, vaccines, central-nervous-system agents, and antineoplastics. About half of the patients received more than the usual dosage. The most common permanent disabilities were brain damage, blindness, tardive dyskinesia, deafness, quadriplegia, and hearing loss. Event types were distributed as medication errors (55%), adverse drug reactions (43%), and drug interactions (2%). Eighty-four percent of the drug-induced permanent disabilities were judged to have been preventable; of these, a pharmacist could have prevented 40%. Litigation was reported for 56% of the cases of drug-induced permanent disability; judgments and settlements averaged $4.3 million. A review of published case reports of ADEs for 1978-97 yielded information on possible risk factors for drug-induced permanent disabilities and on which events may have been preventable.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
P. E. Johnston, D. J. France, D. W. Byrne, H. J. Murff, B. Lee, R. A. Stiles, and T. Speroff
Assessment of adverse drug events among patients in a tertiary care medical center
Am. J. Health Syst. Pharm., November 15, 2006; 63(22): 2218 - 2227.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
W. N. Kelly and T. D. Rucker
Compelling features of a safe medication-use system.
Am. J. Health Syst. Pharm., August 1, 2006; 63(15): 1461 - 1468.
[Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
C. A. Bond and C. L. Raehl
Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy
Am. J. Health Syst. Pharm., August 1, 2005; 62(15): 1596 - 1605.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
W. N Kelly
The Quality of Published Adverse Drug Event Reports
Ann. Pharmacother., December 1, 2003; 37(12): 1774 - 1778.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society of Health-System Pharmacists.